<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chronic_Obstructive_Pulmonary_Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Chronic_Obstructive_Pulmonary_Disease</span>
        </nav>

        <header class="page-header">
            <h1>Chronic_Obstructive_Pulmonary_Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005002" target="_blank">
                        MONDO:0005002
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Respiratory Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Smoking-Related Disease</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">respiratory system disorder</span>
                    
                    <span class="tag tag-classification">obstructive lung disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Chronic Bronchitis</div>
                
                <div class="item-desc">Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23204254" target="_blank">PMID:23204254</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27264777" target="_blank">PMID:27264777</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics."</div>
                
                
                <div class="evidence-explanation">The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22753831" target="_blank">PMID:22753831</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic cough and sputum production: a clinical COPD phenotype?"</div>
                
                
                <div class="evidence-explanation">The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Emphysema</div>
                
                <div class="item-desc">Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33926668" target="_blank">PMID:33926668</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema."</div>
                
                
                <div class="evidence-explanation">This reference reiterates the point that emphysema is a recognized subtype of COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21178627" target="_blank">PMID:21178627</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Latest studies further support the association of emphysema and COPD with coal dust exposure."</div>
                
                
                <div class="evidence-explanation">This confirms that emphysema is considered a subtype of COPD, further supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Airflow Limitation</div>
                
                <div class="item-desc">Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Epithelial Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000066" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        airway remodeling
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23204254" target="_blank">PMID:23204254</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse"</div>
                
                
                <div class="evidence-explanation">This study describes how mucus build-up and epithelial remodeling lead to airflow obstruction in COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36108172" target="_blank">PMID:36108172</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown."</div>
                
                
                <div class="evidence-explanation">This study notes the involvement of epithelial cells in COPD but states that mechanisms remain unknown, partially supporting the role of epithelial cells in airflow obstruction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38625125" target="_blank">PMID:38625125</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic exposure to environmental hazards causes airway epithelial dysfunction, primarily impaired physical barriers, immune dysfunction, and repair or regeneration. Impairment of airway epithelial function subsequently leads to exaggerated airway inflammation and remodeling, the main features..."</div>
                
                
                <div class="evidence-explanation">This study supports the statement by highlighting the role of epithelial dysfunction, inflammation, and remodeling in COPD pathophysiology.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chronic Inflammation</div>
                
                <div class="item-desc">Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T-lymphocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        neutrophil degranulation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17305517" target="_blank">PMID:17305517</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Neutrophils and macrophages have been implicated in this process; they release proteolytic enzymes and generate oxidants, which cause tissue damage, as well as cytokines and chemokines, which can potentiate inflammation and trigger an immune response."</div>
                
                
                <div class="evidence-explanation">The literature describes the involvement of neutrophils, macrophages, and T-lymphocytes in the inflammatory process associated with COPD, supporting the notion of persistent irritation and chronic inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24507838" target="_blank">PMID:24507838</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This inflammation is characterized by increased numbers of alveolar macrophages, neutrophils, and T lymphocytes, which are recruited from the circulation."</div>
                
                
                <div class="evidence-explanation">This article further substantiates the involvement of these cell types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of COPD, linking them to chronic inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38035712" target="_blank">PMID:38035712</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this study, we found that neutrophilic phenotype (NP, 58.0%) was the most common airway inflammation phenotype in patients with COPD, followed by mixed granulocytic phenotype (MGP, 32.6%)."</div>
                
                
                <div class="evidence-explanation">The study indicates that neutrophils are predominant in COPD, supporting the statement about chronic inflammation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Airway Remodeling</div>
                
                <div class="item-desc">Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Smooth Muscle Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000192" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        fibrosis
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20500603" target="_blank">PMID:20500603</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Moreover, airway remodelling occurs not only in asthma but also in several pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and systemic sclerosis."</div>
                
                
                <div class="evidence-explanation">The statement aligns with the mentioned literature which notes airway remodeling as part of chronic obstructive pulmonary disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30257694" target="_blank">PMID:30257694</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Multiple dysfunctions of ASM contribute to modulating airway responses to stimuli, remodeling, and fibrosis, as well as influence the compliance of lungs."</div>
                
                
                <div class="evidence-explanation">The statement is supported as this literature highlights the role of airway smooth muscle cells in airway remodeling and fibrosis in COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15347849" target="_blank">PMID:15347849</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD."</div>
                
                
                <div class="evidence-explanation">The literature supports the statement by confirming the involvement of smooth muscle cells and structural changes in the airways in COPD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Alveolar Destruction</div>
                
                <div class="item-desc">Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Alveolar Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000583" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        proteolysis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006508" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11993785" target="_blank">PMID:11993785</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"In the lung parenchyma, emphysema defined as alveolar destruction and airspace enlargement is present."</div>
                
                
                <div class="evidence-explanation">While the reference supports alveolar destruction as part of COPD&#39;s pathophysiology, it does not mention alveolar macrophages specifically.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29433833" target="_blank">PMID:29433833</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"In inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), despite their increased numbers, macrophages demonstrate significantly reduced phagocytic capacity of bacteria and apoptotic cells."</div>
                
                
                <div class="evidence-explanation">The macrophages&#39; role in the pathophysiology of COPD is discussed, focusing on their reduced phagocytic capacity rather than direct alveolar destruction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32493486" target="_blank">PMID:32493486</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">The role of alveolar macrophages (responsible for the degradation of surfactant) in the development of COPD is mentioned, but no direct link to alveolar destruction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress and Mitochondrial Dysfunction</div>
                
                <div class="item-desc">Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        airway epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002368" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Alveolar Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000583" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        mitochondrion organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007005" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        mitophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000422" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mucus Hypersecretion</div>
                
                <div class="item-desc">Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        goblet cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000160" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        club cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000158" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        mucus secretion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070254" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        cilium movement
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0003341" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">NLRP3 Inflammasome Activation</div>
                
                <div class="item-desc">Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1Œ≤/IL-18 release.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        airway epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002368" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        NLRP3 inflammasome complex assembly
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0072559" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cellular Senescence</div>
                
                <div class="item-desc">Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        airway epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002368" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000057" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cellular senescence
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0090398" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Progressive Respiratory Impairment&#39; (from &#39;Airflow Limitation&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Progressive_Respiratory_Impairment[&#34;Progressive Respiratory Impairment&#34;]
    Airflow_Limitation[&#34;Airflow Limitation&#34;]
    Hypoxemia[&#34;Hypoxemia&#34;]
    Dyspnea[&#34;Dyspnea&#34;]
    Exercise_Intolerance[&#34;Exercise Intolerance&#34;]
    Hypercapnia[&#34;Hypercapnia&#34;]
    Respiratory_Failure[&#34;Respiratory Failure&#34;]

    Airflow_Limitation -.-&gt; Progressive_Respiratory_Impairment
    Dyspnea --&gt; Exercise_Intolerance
    Respiratory_Failure --&gt; Hypoxemia
    Respiratory_Failure --&gt; Hypercapnia

    style Progressive_Respiratory_Impairment fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Airflow_Limitation fill:#dbeafe
    style Hypoxemia fill:#fef3c7
    style Dyspnea fill:#fef3c7
    style Exercise_Intolerance fill:#fef3c7
    style Hypercapnia fill:#fef3c7
    style Respiratory_Failure fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dyspnea
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002094" target="_blank">
                            HP:0002094
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Exercise Intolerance</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28277858" target="_blank">PMID:28277858</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival."</div>
                
                
                <div class="evidence-explanation">The literature supports that dyspnea is a common symptom in COPD and is frequently observed in patients, confirming its categorization as a respiratory phenotype with diagnostic importance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35698999" target="_blank">PMID:35698999</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively."</div>
                
                
                <div class="evidence-explanation">This study highlights the high prevalence of dyspnea in patients with COPD, further supporting its status as a very frequent respiratory phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34972922" target="_blank">PMID:34972922</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Up to date research has shown a positive correlation between the elevated levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while others present ambiguous results"</div>
                
                
                <div class="evidence-explanation">The correlation between dyspnea and COPD is reinforced by the positive association found with certain markers in exhaled breath condensate.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Chronic Cough
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0034315" target="_blank">
                            HP:0034315
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Often productive of mucus</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29881269" target="_blank">PMID:29881269</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Compared with patients without chronic cough, those with chronic cough exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD, more severe dyspnea, and worse QoL."</div>
                
                
                <div class="evidence-explanation">The study identifies chronic cough as a common and significant phenotype in COPD patients, indicating its very frequent occurrence and diagnostic importance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31740261" target="_blank">PMID:31740261</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. This review will discuss the old and new concepts for the different types of COPD phenotypes."</div>
                
                
                <div class="evidence-explanation">The statement mentions the heterogeneity of COPD with multiple phenotypes, which could include phenotypes like chronic cough.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Sputum Production
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0033709" target="_blank">
                            HP:0033709
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Mucus is often difficult to expectorate</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22753831" target="_blank">PMID:22753831</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic cough and sputum production: a clinical COPD phenotype?"</div>
                
                
                <div class="evidence-explanation">The title of the article itself suggests that sputum production is recognized as a phenotype of COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23204254" target="_blank">PMID:23204254</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">Chronic bronchitis, which involves overproduction and hypersecretion of mucus, is described as a common phenomenon in COPD, indicating sputum production is a frequent COPD phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Wheezing
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0030828" target="_blank">
                            HP:0030828
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Due to airflow obstruction</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33302722" target="_blank">PMID:33302722</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The clinical symptoms of this disease include progressive dyspnea, cough, expectoration, and wheezing, among others."</div>
                
                
                <div class="evidence-explanation">The abstract mentions wheezing as one of the clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11963614" target="_blank">PMID:11963614</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Remember, all that wheezes is not asthma; therefore, providers in this case had to determine if the patient was suffering something such as anaphylaxis, asthma, bronchitis, pneumonia or even congestive heart failure (CHF)."</div>
                
                
                <div class="evidence-explanation">The abstract indicates that wheezing can be a symptom of various conditions, including COPD-related bronchospasm.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2404712" target="_blank">PMID:2404712</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increased airways reactivity is present in 15 to 70 percent of patients with chronic airflow obstruction."</div>
                
                
                <div class="evidence-explanation">The abstract discusses increased airway reactivity, which is related to wheezing, in patients with chronic airflow obstruction, including COPD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Barrel Chest
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                </div>
                
                <div class="item-desc">Due to hyperinflation of the lungs</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25159007" target="_blank">PMID:25159007</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lung hyperinflation is highly prevalent in patients with chronic obstructive pulmonary disease and occurs across the continuum of the disease."</div>
                
                
                <div class="evidence-explanation">The reference supports the association of lung hyperinflation with COPD but does not specifically mention &#39;Barrel Chest&#39; or its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34972922" target="_blank">PMID:34972922</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Attempts to connect the products of the analysis of the EBC with the clinical manifestations of COPD such as dyspnea are scarce."</div>
                
                
                <div class="evidence-explanation">The reference discusses the clinical manifestations of COPD but does not specifically mention &#39;Barrel Chest&#39; or its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23204254" target="_blank">PMID:23204254</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">The reference discusses chronic bronchitis in COPD but does not mention &#39;Barrel Chest&#39; or its frequency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Respiratory Failure
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002878" target="_blank">
                            HP:0002878
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Hypoxemia</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Hypercapnia</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14621114" target="_blank">PMID:14621114</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Respiratory failure is still an important complication of chronic obstructive pulmonary disease (COPD) and hospitalisation with an acute episode being a poor prognostic marker."</div>
                
                
                <div class="evidence-explanation">The reference indicates that respiratory failure is an important and common complication of COPD, not an occasional one.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38692758" target="_blank">PMID:38692758</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hypoventilation is a complication that is not uncommon in chronic obstructive pulmonary disease and calls for both medical treatment of the underlying disease and, frequently, noninvasive ventilation either during exacerbations requiring hospitalization or in a chronic state in the patient at home."</div>
                
                
                <div class="evidence-explanation">The reference suggests that hypoventilation, which can lead to respiratory failure, is not uncommon in COPD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33998496" target="_blank">PMID:33998496</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fatigue: A neglected symptom of COPD."</div>
                
                
                <div class="evidence-explanation">The title itself indicates that fatigue is a recognized symptom of COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31729154" target="_blank">PMID:31729154</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fatigue is an important yet ignored symptom of chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">This reference acknowledges fatigue as an important symptom of COPD, supporting its frequent occurrence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24874124" target="_blank">PMID:24874124</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Symptoms in COPD do not solely arise from the degree of airflow obstruction as exercise limitation is compounded by the specific secondary manifestations of the disease including skeletal muscle impairment, osteoporosis, mood disturbance, anemia, and hormonal imbalance."</div>
                
                
                <div class="evidence-explanation">While this reference does not mention fatigue explicitly, it discusses systemic manifestations of COPD, implying the systemic nature of the disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weight Loss
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                            HP:0001824
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">More common in advanced disease</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12406664" target="_blank">PMID:12406664</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Weight loss occurs frequently in patients with chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">The literature states that weight loss is a common phenomenon in COPD patients, which supports the statement that weight loss is a systemic issue in COPD, more common in advanced disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18415812" target="_blank">PMID:18415812</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"These include unintentional weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others."</div>
                
                
                <div class="evidence-explanation">This reference mentions unintentional weight loss as one of the systemic effects of COPD, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36922031" target="_blank">PMID:36922031</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more."</div>
                
                
                <div class="evidence-explanation">The mention of cachexia (underweight) as a comorbidity in COPD patients aligns with the statement about weight loss being more common in advanced disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Exercise Intolerance
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Cardiovascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0003546" target="_blank">
                            HP:0003546
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypoxemia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012418" target="_blank">
                            HP:0012418
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypercapnia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012416" target="_blank">
                            HP:0012416
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SERPINA1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32800189" target="_blank">PMID:32800189</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described."</div>
                
                
                <div class="evidence-explanation">The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35104244" target="_blank">PMID:35104244</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease."</div>
                
                
                <div class="evidence-explanation">The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36630963" target="_blank">PMID:36630963</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    MMP12
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Matrix metalloproteinase-12 contributes to emphysema development.)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NLRP3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Inflammasome activation contributes to chronic inflammation.)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNF
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Tumor necrosis factor mediates systemic and airway inflammation.)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL1B
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Interleukin-1 beta drives inflammatory signaling.)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL6
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Interleukin-6 contributes to systemic inflammation.)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NFE2L2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Nrf2 transcription factor regulates antioxidant defense.)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Smoking Cessation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000077" target="_blank">
                            MAXO:0000077
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Stopping smoking to slow disease progression and improve outcomes.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25496790" target="_blank">PMID:25496790</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality."</div>
                
                
                <div class="evidence-explanation">The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19811377" target="_blank">PMID:19811377</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions."</div>
                
                
                <div class="evidence-explanation">The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11935838" target="_blank">PMID:11935838</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most important intervention is smoking cessation."</div>
                
                
                <div class="evidence-explanation">The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Bronchodilators
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29794201" target="_blank">PMID:29794201</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life."</div>
                
                
                <div class="evidence-explanation">The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27576232" target="_blank">PMID:27576232</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted."</div>
                
                
                <div class="evidence-explanation">This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28757318" target="_blank">PMID:28757318</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease."</div>
                
                
                <div class="evidence-explanation">This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Inhaled Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000312" target="_blank">
                            MAXO:0000312
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Reduce airway inflammation and frequency of exacerbations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20102305" target="_blank">PMID:20102305</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the..."</div>
                
                
                <div class="evidence-explanation">While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37348121" target="_blank">PMID:37348121</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Current pharmacologic strategies, including first- and second-line therapies such as long-acting Œ≤2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD"</div>
                
                
                <div class="evidence-explanation">ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29938633" target="_blank">PMID:29938633</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids."</div>
                
                
                <div class="evidence-explanation">The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Phosphodiesterase-4 Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Reduce inflammation and relax airways.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15699784" target="_blank">PMID:15699784</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils."</div>
                
                
                <div class="evidence-explanation">The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20649375" target="_blank">PMID:20649375</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress."</div>
                
                
                <div class="evidence-explanation">Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34731461" target="_blank">PMID:34731461</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure."</div>
                
                
                <div class="evidence-explanation">This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Oxygen Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000503" target="_blank">
                            MAXO:0000503
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Long-term oxygen use for patients with severe chronic hypoxemia.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24461631" target="_blank">PMID:24461631</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure."</div>
                
                
                <div class="evidence-explanation">The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37353334" target="_blank">PMID:37353334</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD."</div>
                
                
                <div class="evidence-explanation">This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19462352" target="_blank">PMID:19462352</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD."</div>
                
                
                <div class="evidence-explanation">This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Pulmonary Rehabilitation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Exercise training, education, and support to improve quality of life and physical conditioning.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29526182" target="_blank">PMID:29526182</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD."</div>
                
                
                <div class="evidence-explanation">The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement&#39;s description of treatments including exercise training, education, and support.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34338012" target="_blank">PMID:34338012</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement&#39;s claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34955635" target="_blank">PMID:34955635</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lung Volume Reduction Surgery
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Surgical removal of damaged lung tissue for severe emphysema.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22189668" target="_blank">PMID:22189668</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema."</div>
                
                
                <div class="evidence-explanation">The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33926668" target="_blank">PMID:33926668</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema."</div>
                
                
                <div class="evidence-explanation">The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31145187" target="_blank">PMID:31145187</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity."</div>
                
                
                <div class="evidence-explanation">The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lung Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Considered in end-stage COPD with severe impairment.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17240617" target="_blank">PMID:17240617</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD."</div>
                
                
                <div class="evidence-explanation">This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31375190" target="_blank">PMID:31375190</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states."</div>
                
                
                <div class="evidence-explanation">The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36050206" target="_blank">PMID:36050206</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease."</div>
                
                
                <div class="evidence-explanation">This source concentrates on lung transplantation for patients with COPD, in line with the statement&#39;s context of it being a treatment for end-stage COPD.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Mucolytic Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Macrolide Antibiotics
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Biologic Therapies
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Smoking</div>
                
                <div class="item-desc">Primary risk factor for development and progression.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30810540" target="_blank">PMID:30810540</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD."</div>
                
                
                <div class="evidence-explanation">This clearly identifies smoking as a major risk factor for COPD development.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31759959" target="_blank">PMID:31759959</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The observation that COPD is an independent risk factor for cardiovascular disease (CVDs) comes from comparisons between smokers with COPD and smokers without COPD."</div>
                
                
                <div class="evidence-explanation">This snippet highlights the relationship between smoking, COPD, and other health issues, indirectly supporting smoking as a risk factor for COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28933915" target="_blank">PMID:28933915</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">Directly states that cigarette smoke is the primary risk factor for COPD development.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Air Pollution</div>
                
                <div class="item-desc">Exposure to pollutants can exacerbate symptoms.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33542053" target="_blank">PMID:33542053</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients&#39; health."</div>
                
                
                <div class="evidence-explanation">This study found that exposure to various air pollutants adversely affects the health of COPD patients, supporting the idea that air pollution exacerbates COPD symptoms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25673984" target="_blank">PMID:25673984</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses."</div>
                
                
                <div class="evidence-explanation">This reference discusses environmental factors, including pollutants, that contribute to oxidative stress and inflammation in COPD, thus supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37068517" target="_blank">PMID:37068517</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Harmful inhaled workplace exposures can contribute to the development of chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">This statement supports the environmental influence on COPD, including air pollutants, as a risk factor.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Occupational Dust and Chemicals</div>
                
                <div class="item-desc">Long-term exposure increases risk.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11964759" target="_blank">PMID:11964759</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease"</div>
                
                
                <div class="evidence-explanation">The abstract confirms that occupational exposure to dusts, chemicals, and gases is a well-supported risk factor for chronic obstructive pulmonary disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20535848" target="_blank">PMID:20535848</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lung function loss associated with occupational dust exposure in metal smelting"</div>
                
                
                <div class="evidence-explanation">This study provides evidence of lung function loss due to occupational dust exposure, supporting the assertion that long-term exposure to such environmental factors increases the risk of chronic obstructive pulmonary disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23361196" target="_blank">PMID:23361196</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD)"</div>
                
                
                <div class="evidence-explanation">The abstract discusses the recognized contribution of workplace exposures, including textile dust, to chronic obstructive pulmonary disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Arterial Blood Gases
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Altered)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21812941" target="_blank">PMID:21812941</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients."</div>
                
                
                <div class="evidence-explanation">The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34756790" target="_blank">PMID:34756790</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation."</div>
                
                
                <div class="evidence-explanation">The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25119324" target="_blank">PMID:25119324</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD)."</div>
                
                
                <div class="evidence-explanation">While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    C-Reactive Protein (CRP)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: General inflammation and exacerbations.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23206444" target="_blank">PMID:23206444</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47)."</div>
                
                
                <div class="evidence-explanation">This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24313775" target="_blank">PMID:24313775</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available."</div>
                
                
                <div class="evidence-explanation">The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24102428" target="_blank">PMID:24102428</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Serum CRP levels were also significantly higher on D1 compared to D7 (p &lt; 0.001)."</div>
                
                
                <div class="evidence-explanation">The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Chronic_Obstructive_Pulmonary_Disease
category: Complex
parents:
- Respiratory Disease
- Smoking-Related Disease
has_subtypes:
- name: Chronic Bronchitis
  description: Inflammation of the bronchial tubes leading to increased mucus production
    and chronic cough.
  evidence:
  - reference: PMID:23204254
    supports: SUPPORT
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic
      obstructive pulmonary disease (COPD).
    explanation: The article clearly states that Chronic Bronchitis (CB) is a subtype
      of COPD, characterized by inflammation of the bronchial tubes leading to increased
      mucus production and chronic cough.
  - reference: PMID:27264777
    supports: SUPPORT
    snippet: Chronic obstructive pulmonary disease (COPD) is an umbrella term that
      covers many clinical subtypes with clearly different pulmonary and extra-pulmonary
      characteristics.
    explanation: The article supports that COPD has multiple subtypes with differing
      characteristics, encompassing conditions like Chronic Bronchitis.
  - reference: PMID:22753831
    supports: SUPPORT
    snippet: &#39;Chronic cough and sputum production: a clinical COPD phenotype?&#39;
    explanation: The article discusses the phenotype of COPD which includes chronic
      cough and sputum production, indicative of conditions like Chronic Bronchitis.
- name: Emphysema
  description: Damage to the alveoli resulting in shortness of breath and reduced
    surface area for gas exchange.
  evidence:
  - reference: PMID:33926668
    supports: SUPPORT
    snippet: &#39;Chronic obstructive pulmonary usually is subcategorized into 2 groups:
      chronic bronchitis and emphysema.&#39;
    explanation: This reference reiterates the point that emphysema is a recognized
      subtype of COPD.
  - reference: PMID:21178627
    supports: SUPPORT
    snippet: Latest studies further support the association of emphysema and COPD
      with coal dust exposure.
    explanation: This confirms that emphysema is considered a subtype of COPD, further
      supporting the statement.
prevalence:
- population: Global
  percentage: 11.7
  evidence:
  - reference: PMID:35261410
    supports: NO_EVIDENCE
    snippet: &#39;The estimated pooled prevalence of COPD was 11.1% (95% confidence interval,
      CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease
      fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal
      criteria.&#39;
    explanation: The study provides prevalence data for specific regions (e.g., South
      Asia) but does not mention a global prevalence rate of 11.7%.
  - reference: PMID:37461046
    supports: NO_EVIDENCE
    snippet: Though disease burden of silicosis has been on a decline in general from
      1990 to 2019, which shows a promising prospect but cannot be ignored.
    explanation: This study focuses on the global incidence, prevalence, and disease
      burden of silicosis, not COPD.
progression:
- phase: Onset
  notes: Typically begins in individuals over the age of 40.
  evidence:
  - reference: PMID:26154786
    supports: PARTIAL
    snippet: Among 657 persons who had an FEV1 of less than 80% of the predicted value
      before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas
      among 2207 persons who had a baseline FEV1 of at least 80% of the predicted
      value before 40 years of age, 158 (7%) had COPD after 22 years of observation.
    explanation: The literature suggests that COPD can develop in individuals with
      low FEV1 before the age of 40. While this supports the idea that COPD typically
      begins in individuals over 40, it also indicates that it can start earlier in
      some cases.
  - reference: PMID:19934351
    supports: SUPPORT
    snippet: There is growing evidence of higher prevalence of chronic obstructive
      pulmonary disease (COPD) in the elderly. Age-associated changes in the structure
      and function of the lung may increase a pathogenetic susceptibility to COPD.
    explanation: This reference supports the statement that COPD typically begins
      in individuals over the age of 40, particularly due to age-associated changes
      in lung structure and function.
pathophysiology:
- name: Airflow Limitation
  description: Obstruction of airflow due to inflammation, mucus build-up, and remodeling
    of the airways.
  cell_types:
  - preferred_term: Epithelial Cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: airway remodeling
    description: Structural changes in airway architecture
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  downstream:
  - target: Progressive Respiratory Impairment
    description: Chronic airway inflammation and remodeling lead to progressive airflow
      obstruction and respiratory decline.
    evidence:
    - reference: PMID:39046133
      supports: SUPPORT
      snippet: Chronic exposure to smoking and noxious particles or gases induces inflammation and remodeling, leading to airway obstruction and SAD, eventually resulting in complete airway loss.
      explanation: This 2024 review establishes that chronic inflammation and remodeling cause irreversible airflow limitation and progressive respiratory decline in COPD.
  evidence:
  - reference: PMID:23204254
    supports: SUPPORT
    snippet: CB is caused by overproduction and hypersecretion of mucus by goblet
      cells, which leads to worsening airflow obstruction by luminal obstruction of
      small airways, epithelial remodeling, and alteration of airway surface tension
      predisposing to collapse
    explanation: This study describes how mucus build-up and epithelial remodeling
      lead to airflow obstruction in COPD.
  - reference: PMID:36108172
    supports: PARTIAL
    snippet: Phenotypic alterations in the lung epithelium have been widely implicated
      in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise
      mechanisms orchestrating this persistent inflammatory process remain unknown.
    explanation: This study notes the involvement of epithelial cells in COPD but
      states that mechanisms remain unknown, partially supporting the role of epithelial
      cells in airflow obstruction.
  - reference: PMID:38625125
    supports: SUPPORT
    snippet: Chronic exposure to environmental hazards causes airway epithelial dysfunction,
      primarily impaired physical barriers, immune dysfunction, and repair or regeneration.
      Impairment of airway epithelial function subsequently leads to exaggerated airway
      inflammation and remodeling, the main features of chronic obstructive pulmonary
      disease (COPD).
    explanation: This study supports the statement by highlighting the role of epithelial
      dysfunction, inflammation, and remodeling in COPD pathophysiology.
- name: Chronic Inflammation
  description: Persistent irritation from inhaled substances like cigarette smoke
    leads to airway and alveolar inflammation.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T-lymphocyte
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  evidence:
  - reference: PMID:17305517
    supports: SUPPORT
    snippet: Neutrophils and macrophages have been implicated in this process; they
      release proteolytic enzymes and generate oxidants, which cause tissue damage,
      as well as cytokines and chemokines, which can potentiate inflammation and trigger
      an immune response.
    explanation: The literature describes the involvement of neutrophils, macrophages,
      and T-lymphocytes in the inflammatory process associated with COPD, supporting
      the notion of persistent irritation and chronic inflammation.
  - reference: PMID:24507838
    supports: SUPPORT
    snippet: This inflammation is characterized by increased numbers of alveolar macrophages,
      neutrophils, and T lymphocytes, which are recruited from the circulation.
    explanation: This article further substantiates the involvement of these cell
      types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of
      COPD, linking them to chronic inflammation.
  - reference: PMID:38035712
    supports: SUPPORT
    snippet: In this study, we found that neutrophilic phenotype (NP, 58.0%) was the
      most common airway inflammation phenotype in patients with COPD, followed by
      mixed granulocytic phenotype (MGP, 32.6%).
    explanation: The study indicates that neutrophils are predominant in COPD, supporting
      the statement about chronic inflammation.
  - reference: PMID:38891820
    supports: SUPPORT
    snippet: Recent multiomics-based evidence suggests that the plasticity of alveolar
      macrophages contributes to the onset and progression of COPD through the coordinated
      modulation of numerous transcription factors.
    explanation: The article highlights the role of macrophages in the pathogenesis
      and progression of COPD, thus supporting the statement.
  - reference: PMID:11993785
    supports: PARTIAL
    snippet: The characteristic changes in the central airways include inflammatory
      cellular infiltration into the airway wall and mucous gland enlargement.
    explanation: This reference provides a broader overview of the pathological changes
      in COPD, mentioning inflammatory cells but not specifically detailing the involvement
      of neutrophils, macrophages, and T-lymphocytes.
- name: Airway Remodeling
  description: Structural changes in the airway due to chronic inflammation, including
    fibrosis and increased airway thickness.
  cell_types:
  - preferred_term: Smooth Muscle Cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: fibrosis
    description: Excessive deposition of connective tissue
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  evidence:
  - reference: PMID:20500603
    supports: SUPPORT
    snippet: Moreover, airway remodelling occurs not only in asthma but also in several
      pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic
      pulmonary fibrosis and systemic sclerosis.
    explanation: The statement aligns with the mentioned literature which notes airway
      remodeling as part of chronic obstructive pulmonary disease.
  - reference: PMID:30257694
    supports: SUPPORT
    snippet: Multiple dysfunctions of ASM contribute to modulating airway responses
      to stimuli, remodeling, and fibrosis, as well as influence the compliance of
      lungs.
    explanation: The statement is supported as this literature highlights the role
      of airway smooth muscle cells in airway remodeling and fibrosis in COPD.
  - reference: PMID:15347849
    supports: SUPPORT
    snippet: Increases in airway smooth muscle mass occur in large airways of severe
      asthmatics and in small airways of patients with COPD.
    explanation: The literature supports the statement by confirming the involvement
      of smooth muscle cells and structural changes in the airways in COPD.
- name: Alveolar Destruction
  description: Breakdown of alveolar walls, leading to reduced surface area for gas
    exchange and loss of lung elasticity.
  cell_types:
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  - preferred_term: lung parenchyma
    term:
      id: UBERON:0008946
      label: lung parenchyma
  evidence:
  - reference: PMID:11993785
    supports: PARTIAL
    snippet: In the lung parenchyma, emphysema defined as alveolar destruction and
      airspace enlargement is present.
    explanation: While the reference supports alveolar destruction as part of COPD&#39;s
      pathophysiology, it does not mention alveolar macrophages specifically.
  - reference: PMID:29433833
    supports: PARTIAL
    snippet: In inflammatory lung diseases such as chronic obstructive pulmonary disease
      (COPD), despite their increased numbers, macrophages demonstrate significantly
      reduced phagocytic capacity of bacteria and apoptotic cells.
    explanation: The macrophages&#39; role in the pathophysiology of COPD is discussed,
      focusing on their reduced phagocytic capacity rather than direct alveolar destruction.
  - reference: PMID:32493486
    supports: PARTIAL
    snippet: External insults like smoke and pollution can disturb surfactant homeostasis
      and result in either surfactant insufficiency or accumulation. But disruption
      of surfactant homeostasis is also observed in many chronic adult diseases, including
      chronic obstructive pulmonary disease (COPD).
    explanation: The role of alveolar macrophages (responsible for the degradation
      of surfactant) in the development of COPD is mentioned, but no direct link to
      alveolar destruction.
  - reference: PMID:24707174
    supports: PARTIAL
    snippet: &#39;There are eight types of EMPs which are defined by the presence of different
      endothelial markers on the cell membrane: vascular endothelial-cadherin; platelet
      endothelial cell adhesion molecule; melanoma cell adhesion molecule; E-selectin;
      CD51; CD105; von Willebrand factor; and CD143 EMPs.&#39;
    explanation: The reference discusses endothelial injury and microparticles in
      COPD, which may indirectly relate to alveolar destruction, but does not directly
      address it or the role of alveolar macrophages.
- name: Oxidative Stress and Mitochondrial Dysfunction
  description: Cigarette smoke and pollutants trigger mitochondrial ROS production,
    impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.
  cell_types:
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: mitophagy
    term:
      id: GO:0000422
      label: mitophagy
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  notes: Reduced Nrf2 and SIRT1 activity diminishes antioxidant capacity; mitochondrial
    ROS activates NLRP3 inflammasome.
- name: Mucus Hypersecretion
  description: Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired
    mucociliary clearance contribute to mucus plugging.
  cell_types:
  - preferred_term: goblet cell
    term:
      id: CL:0000160
      label: goblet cell
  - preferred_term: club cell
    term:
      id: CL:0000158
      label: club cell
  biological_processes:
  - preferred_term: mucus secretion
    term:
      id: GO:0070254
      label: mucus secretion
  - preferred_term: cilium movement
    term:
      id: GO:0003341
      label: cilium movement
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  notes: MUC5AC/MUC5B overexpression and club-to-goblet transdifferentiation impair
    airway clearance.
- name: NLRP3 Inflammasome Activation
  description: Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome,
    leading to caspase-1 activation and IL-1Œ≤/IL-18 release.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  biological_processes:
  - preferred_term: NLRP3 inflammasome complex assembly
    term:
      id: GO:0072559
      label: NLRP3 inflammasome complex assembly
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  notes: PM2.5 and cigarette smoke synergize to activate NLRP3/caspase-1 signaling.
- name: Cellular Senescence
  description: Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated
    secretory phenotype (SASP), promoting chronic inflammation and remodeling.
  cell_types:
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: cellular senescence
    term:
      id: GO:0090398
      label: cellular senescence
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  notes: SASP factors include IL-6, CXCL8, and MMPs; senolytic therapies are under
    investigation.
phenotypes:
- category: Respiratory
  name: Dyspnea
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:28277858
    supports: SUPPORT
    snippet: Indeed, it is an important symptom in chronic obstructive pulmonary disease
      (COPD), where it is associated with limited physical activity, increased anxiety
      and depression, decreased health-related quality of life (HRQoL), and reduced
      survival.
    explanation: The literature supports that dyspnea is a common symptom in COPD
      and is frequently observed in patients, confirming its categorization as a respiratory
      phenotype with diagnostic importance.
  - reference: PMID:35698999
    supports: SUPPORT
    snippet: Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease
      (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence
      interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively.
    explanation: This study highlights the high prevalence of dyspnea in patients
      with COPD, further supporting its status as a very frequent respiratory phenotype.
  - reference: PMID:34972922
    supports: SUPPORT
    snippet: Up to date research has shown a positive correlation between the elevated
      levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while
      others present ambiguous results
    explanation: The correlation between dyspnea and COPD is reinforced by the positive
      association found with certain markers in exhaled breath condensate.
  sequelae:
  - target: Exercise Intolerance
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Respiratory
  name: Chronic Cough
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:29881269
    supports: SUPPORT
    snippet: Compared with patients without chronic cough, those with chronic cough
      exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing
      capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD,
      more severe dyspnea, and worse QoL.
    explanation: The study identifies chronic cough as a common and significant phenotype
      in COPD patients, indicating its very frequent occurrence and diagnostic importance.
  - reference: PMID:31740261
    supports: SUPPORT
    snippet: COPD is now widely accepted as a heterogeneous condition with multiple
      phenotypes and endotypes. This review will discuss the old and new concepts
      for the different types of COPD phenotypes.
    explanation: The statement mentions the heterogeneity of COPD with multiple phenotypes,
      which could include phenotypes like chronic cough.
  notes: Often productive of mucus
  phenotype_term:
    preferred_term: Chronic Cough
    term:
      id: HP:0034315
      label: Chronic cough
- category: Respiratory
  name: Sputum Production
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:22753831
    supports: SUPPORT
    snippet: &#39;Chronic cough and sputum production: a clinical COPD phenotype?&#39;
    explanation: The title of the article itself suggests that sputum production is
      recognized as a phenotype of COPD.
  - reference: PMID:23204254
    supports: SUPPORT
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic
      obstructive pulmonary disease (COPD).
    explanation: Chronic bronchitis, which involves overproduction and hypersecretion
      of mucus, is described as a common phenomenon in COPD, indicating sputum production
      is a frequent COPD phenotype.
  notes: Mucus is often difficult to expectorate
  phenotype_term:
    preferred_term: Sputum Production
    term:
      id: HP:0033709
      label: Increased sputum production
- category: Respiratory
  frequency: FREQUENT
  name: Wheezing
  notes: Due to airflow obstruction
  evidence:
  - reference: PMID:33302722
    supports: SUPPORT
    snippet: The clinical symptoms of this disease include progressive dyspnea, cough,
      expectoration, and wheezing, among others.
    explanation: The abstract mentions wheezing as one of the clinical symptoms of
      Chronic Obstructive Pulmonary Disease (COPD).
  - reference: PMID:11963614
    supports: SUPPORT
    snippet: Remember, all that wheezes is not asthma; therefore, providers in this
      case had to determine if the patient was suffering something such as anaphylaxis,
      asthma, bronchitis, pneumonia or even congestive heart failure (CHF).
    explanation: The abstract indicates that wheezing can be a symptom of various
      conditions, including COPD-related bronchospasm.
  - reference: PMID:2404712
    supports: SUPPORT
    snippet: Increased airways reactivity is present in 15 to 70 percent of patients
      with chronic airflow obstruction.
    explanation: The abstract discusses increased airway reactivity, which is related
      to wheezing, in patients with chronic airflow obstruction, including COPD.
  phenotype_term:
    preferred_term: Wheezing
    term:
      id: HP:0030828
      label: Wheezing
- category: Respiratory
  frequency: OCCASIONAL
  name: Barrel Chest
  notes: Due to hyperinflation of the lungs
  evidence:
  - reference: PMID:25159007
    supports: PARTIAL
    snippet: Lung hyperinflation is highly prevalent in patients with chronic obstructive
      pulmonary disease and occurs across the continuum of the disease.
    explanation: The reference supports the association of lung hyperinflation with
      COPD but does not specifically mention &#39;Barrel Chest&#39; or its frequency.
  - reference: PMID:34972922
    supports: PARTIAL
    snippet: Attempts to connect the products of the analysis of the EBC with the
      clinical manifestations of COPD such as dyspnea are scarce.
    explanation: The reference discusses the clinical manifestations of COPD but does
      not specifically mention &#39;Barrel Chest&#39; or its frequency.
  - reference: PMID:23204254
    supports: NO_EVIDENCE
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic
      obstructive pulmonary disease (COPD).
    explanation: The reference discusses chronic bronchitis in COPD but does not mention
      &#39;Barrel Chest&#39; or its frequency.
- category: Respiratory
  frequency: OCCASIONAL
  name: Respiratory Failure
  sequelae:
  - target: Hypoxemia
  - target: Hypercapnia
  evidence:
  - reference: PMID:14621114
    supports: REFUTE
    snippet: Respiratory failure is still an important complication of chronic obstructive
      pulmonary disease (COPD) and hospitalisation with an acute episode being a poor
      prognostic marker.
    explanation: The reference indicates that respiratory failure is an important
      and common complication of COPD, not an occasional one.
  - reference: PMID:38692758
    supports: REFUTE
    snippet: Hypoventilation is a complication that is not uncommon in chronic obstructive
      pulmonary disease and calls for both medical treatment of the underlying disease
      and, frequently, noninvasive ventilation either during exacerbations requiring
      hospitalization or in a chronic state in the patient at home.
    explanation: The reference suggests that hypoventilation, which can lead to respiratory
      failure, is not uncommon in COPD.
  phenotype_term:
    preferred_term: Respiratory Failure
    term:
      id: HP:0002878
      label: Respiratory failure
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  evidence:
  - reference: PMID:33998496
    supports: SUPPORT
    snippet: &#39;Fatigue: A neglected symptom of COPD.&#39;
    explanation: The title itself indicates that fatigue is a recognized symptom of
      COPD.
  - reference: PMID:31729154
    supports: SUPPORT
    snippet: Fatigue is an important yet ignored symptom of chronic obstructive pulmonary
      disease (COPD).
    explanation: This reference acknowledges fatigue as an important symptom of COPD,
      supporting its frequent occurrence.
  - reference: PMID:24874124
    supports: SUPPORT
    snippet: Symptoms in COPD do not solely arise from the degree of airflow obstruction
      as exercise limitation is compounded by the specific secondary manifestations
      of the disease including skeletal muscle impairment, osteoporosis, mood disturbance,
      anemia, and hormonal imbalance.
    explanation: While this reference does not mention fatigue explicitly, it discusses
      systemic manifestations of COPD, implying the systemic nature of the disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Systemic
  frequency: OCCASIONAL
  name: Weight Loss
  notes: More common in advanced disease
  evidence:
  - reference: PMID:12406664
    supports: SUPPORT
    snippet: Weight loss occurs frequently in patients with chronic obstructive pulmonary
      disease (COPD).
    explanation: The literature states that weight loss is a common phenomenon in
      COPD patients, which supports the statement that weight loss is a systemic issue
      in COPD, more common in advanced disease.
  - reference: PMID:18415812
    supports: SUPPORT
    snippet: These include unintentional weight loss, skeletal muscle dysfunction,
      an increased risk of cardiovascular disease, osteoporosis, and depression, among
      others.
    explanation: This reference mentions unintentional weight loss as one of the systemic
      effects of COPD, supporting the statement.
  - reference: PMID:36922031
    supports: SUPPORT
    snippet: COPD patients with psychological (high anxiety and depression) and cachectic
      (underweight and osteoporotic) comorbidity have higher mortality and exacerbate
      more.
    explanation: The mention of cachexia (underweight) as a comorbidity in COPD patients
      aligns with the statement about weight loss being more common in advanced disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Cardiovascular
  name: Exercise Intolerance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Exercise Intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
- category: Respiratory
  name: Hypoxemia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypoxemia
    term:
      id: HP:0012418
      label: Hypoxemia
- category: Respiratory
  name: Hypercapnia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypercapnia
    term:
      id: HP:0012416
      label: Hypercapnia
biochemical:
- name: Arterial Blood Gases
  presence: Altered
  notes: May show hypoxemia and hypercapnia.
  evidence:
  - reference: PMID:21812941
    supports: PARTIAL
    snippet: The aim of this study was to identify predictors of hypoxemia, hypercapnia
      and increased alveolar-arterial oxygen difference in COPD patients.
    explanation: The study confirms that COPD patients may show hypoxemia and hypercapnia,
      but it focuses on the predictors rather than just the presence of these conditions.
  - reference: PMID:34756790
    supports: SUPPORT
    snippet: Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic
      response, and mild hyperfibrinolysis were probably related to the combined effect
      of nitrogen compounds and the inhaled toxic products of detonation.
    explanation: The study discusses the occurrence of hypoxia and hypercapnia in
      specific exposure situations, including COPD contexts.
  - reference: PMID:25119324
    supports: SUPPORT
    snippet: The prevalence of this sampling method has grown among health professionals,
      coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular
      for those who have chronic obstructive pulmonary disease (COPD).
    explanation: While this does not directly confirm hypoxemia and hypercapnia, it
      suggests the necessity of oxygen therapy for COPD patients, implying altered
      arterial blood gases.
  - reference: PMID:18044093
    supports: SUPPORT
    snippet: Patients with COPD may show slow, progressive deteriorations in arterial
      blood gases during the night, particularly during rapid eye movement (REM) sleep.
      This is mainly due to hypoventilation... The severity of gas exchanges alterations
      is proportional to the degree of impairment of diurnal pulmonary function tests,
      particularly of partial pressure of oxygen (PaO2) and of carbon dioxide (PaCO2)
      in arterial blood...
    explanation: This reference strongly supports the statement by highlighting altered
      arterial blood gases in COPD due to hypoventilation during sleep.
- name: C-Reactive Protein (CRP)
  presence: Elevated
  context: General inflammation and exacerbations.
  evidence:
  - reference: PMID:23206444
    supports: SUPPORT
    snippet: Patients with COPD had higher serum CRP concentrations than healthy controls
      (WMD 4.72 mg/l, 95% CI 2.98, 6.47).
    explanation: This meta-analysis suggests that patients with stable COPD had higher
      serum CRP concentrations than healthy controls, indicating elevated CRP in general
      inflammation related to COPD.
  - reference: PMID:24313775
    supports: SUPPORT
    snippet: These biomarkers include C-reactive protein, procalcitonin, and peripheral
      blood eosinophil count, which are readily available.
    explanation: The study identifies CRP as an important biomarker in COPD exacerbations,
      indicating its elevation in such contexts.
  - reference: PMID:24102428
    supports: SUPPORT
    snippet: Serum CRP levels were also significantly higher on D1 compared to D7
      (p &lt; 0.001).
    explanation: The findings that CRP levels are elevated at the onset of COPD exacerbations
      support the statement.
  - reference: PMID:26595735
    supports: SUPPORT
    snippet: A number of studies support the conclusion that immune dysfunction leads
      to exacerbations and disease severity in COPD.
    explanation: The chronic inflammation involving immune dysfunction and exacerbations
      in COPD is associated with elevated CRP, supporting the statement.
  - reference: PMID:37082823
    supports: SUPPORT
    snippet: Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP),
      and granulocyte colony stimulating factor (G-CSF) were higher in participants
      with OVS and COPD compared with healthy controls and participants with OSA.
    explanation: Elevated hs-CRP in COPD patients relative to healthy controls supports
      the general inflammation and exacerbation context.
genetic:
- name: SERPINA1
  association: Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.
  notes: Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease
    imbalance and emphysema.
  evidence:
  - reference: PMID:32800189
    supports: SUPPORT
    snippet: Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor
      for chronic obstructive pulmonary disease (COPD) described.
    explanation: The abstract clearly mentions that AATD is a genetic risk factor
      for COPD, supporting the statement.
  - reference: PMID:35104244
    supports: SUPPORT
    snippet: Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause
      and risk factor for chronic obstructive pulmonary disease.
    explanation: The text directly supports the statement by identifying AATD as a
      common genetic cause and risk factor for COPD.
  - reference: PMID:36630963
    supports: SUPPORT
    snippet: Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency
      (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient
      AAT activity in the lung manifesting as chronic obstructive pulmonary disease
      (COPD).
    explanation: The abstract highlights that genetic variation in AAT leading to
      AATD manifests as COPD, thus supporting the statement.
- name: MMP12
  association: Matrix metalloproteinase-12 contributes to emphysema development.
  notes: Macrophage-derived protease that degrades elastin and extracellular matrix.
- name: NLRP3
  association: Inflammasome activation contributes to chronic inflammation.
  notes: Activated by mitochondrial ROS and particulate exposures, leading to IL-1Œ≤
    and IL-18 release.
- name: TNF
  association: Tumor necrosis factor mediates systemic and airway inflammation.
  notes: Key pro-inflammatory cytokine in COPD pathogenesis.
- name: IL1B
  association: Interleukin-1 beta drives inflammatory signaling.
  notes: Product of NLRP3 inflammasome activation.
- name: IL6
  association: Interleukin-6 contributes to systemic inflammation.
  notes: Elevated in serum and associated with COPD comorbidities.
- name: NFE2L2
  association: Nrf2 transcription factor regulates antioxidant defense.
  notes: Reduced activity impairs response to oxidative stress in COPD.
environmental:
- name: Smoking
  notes: Primary risk factor for development and progression.
  evidence:
  - reference: PMID:30810540
    supports: SUPPORT
    snippet: Although cigarette smoking is the major risk factor, only 10-20% of smokers
      develop COPD.
    explanation: This clearly identifies smoking as a major risk factor for COPD development.
  - reference: PMID:31759959
    supports: SUPPORT
    snippet: The observation that COPD is an independent risk factor for cardiovascular
      disease (CVDs) comes from comparisons between smokers with COPD and smokers
      without COPD.
    explanation: This snippet highlights the relationship between smoking, COPD, and
      other health issues, indirectly supporting smoking as a risk factor for COPD.
  - reference: PMID:28933915
    supports: SUPPORT
    snippet: The epithelial lining of the airway forms the first barrier against environmental
      insults, such as inhaled cigarette smoke, which is the primary risk factor for
      the development of chronic obstructive pulmonary disease (COPD).
    explanation: Directly states that cigarette smoke is the primary risk factor for
      COPD development.
  - reference: PMID:18303418
    supports: SUPPORT
    snippet: Approximately one-quarter of smokers can be affected by clinically significant
      chronic obstructive pulmonary disease. ... Smokers may reduce their risk of
      developing chronic obstructive pulmonary disease by physical activity and increase
      their survival by smoking reduction.
    explanation: This supports the statement by highlighting the prevalence of COPD
      among smokers and the role of smoking in disease progression.
  - reference: PMID:37429033
    supports: SUPPORT
    snippet: &#39;Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive
      Pulmonary Disease in Later Life.&#39;
    explanation: This implies that smoking is a risk factor in the development of
      COPD.
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
- name: Air Pollution
  notes: Exposure to pollutants can exacerbate symptoms.
  evidence:
  - reference: PMID:33542053
    supports: SUPPORT
    snippet: Our findings suggest that, when considering total personal exposure to
      air pollutants, mainly the gaseous pollutants affect COPD patients&#39; health.
    explanation: This study found that exposure to various air pollutants adversely
      affects the health of COPD patients, supporting the idea that air pollution
      exacerbates COPD symptoms.
  - reference: PMID:25673984
    supports: SUPPORT
    snippet: The major pathogenic factors causing disease include infection and inflammation,
      protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant
      defenses.
    explanation: This reference discusses environmental factors, including pollutants,
      that contribute to oxidative stress and inflammation in COPD, thus supporting
      the statement.
  - reference: PMID:37068517
    supports: SUPPORT
    snippet: Harmful inhaled workplace exposures can contribute to the development
      of chronic obstructive pulmonary disease (COPD).
    explanation: This statement supports the environmental influence on COPD, including
      air pollutants, as a risk factor.
  - reference: PMID:16916323
    supports: SUPPORT
    snippet: Evidence from epidemiological studies finding consistent associations
      between air pollution and various outcomes (respiratory symptoms, reduced lung
      function, chronic bronchitis and mortality), has suggested that outdoor air
      pollution is a contributing cause of morbidity and mortality.
    explanation: This reference directly links air pollution to exacerbation and pathogenesis
      of COPD, supporting the statement.
  - reference: PMID:27751401
    supports: SUPPORT
    snippet: We focus on the major constituents of air pollutants and their impacts
      on chronic respiratory diseases.
    explanation: This review highlights the detrimental effects of air pollution on
      respiratory health, particularly in the discussion on chronic respiratory diseases
      such as COPD.
  exposure_term:
    preferred_term: Air pollution exposure
    term:
      id: ECTO:8000036
      label: exposure to air pollution
- name: Occupational Dust and Chemicals
  notes: Long-term exposure increases risk.
  evidence:
  - reference: PMID:11964759
    supports: SUPPORT
    snippet: occupational exposure to dusts, chemicals and gases will be considered
      an established, or supported by good evidence, risk factor for chronic obstructive
      pulmonary disease
    explanation: The abstract confirms that occupational exposure to dusts, chemicals,
      and gases is a well-supported risk factor for chronic obstructive pulmonary
      disease.
  - reference: PMID:20535848
    supports: SUPPORT
    snippet: Lung function loss associated with occupational dust exposure in metal
      smelting
    explanation: This study provides evidence of lung function loss due to occupational
      dust exposure, supporting the assertion that long-term exposure to such environmental
      factors increases the risk of chronic obstructive pulmonary disease.
  - reference: PMID:23361196
    supports: SUPPORT
    snippet: Recent studies have recognized the contribution of workplace exposures
      to chronic lung diseases, in particular chronic obstructive pulmonary disease
      (COPD)
    explanation: The abstract discusses the recognized contribution of workplace exposures,
      including textile dust, to chronic obstructive pulmonary disease.
  - reference: PMID:24278358
    supports: SUPPORT
    snippet: Occupational inhalative exposure to bg-dust was associated with a statistically
      significant decreased FEV1 and FEV1/FVC revealing airway obstruction consistent
      with COPD
    explanation: The meta-analysis presented indicates a significant association between
      occupational exposure to inorganic dust and the development of chronic obstructive
      pulmonary disease.
  - reference: PMID:35409627
    supports: SUPPORT
    snippet: Pesticides in general and especially organophosphate and carbamate insecticides...
      showed an association, and cadmium (Cd), chromium (Cr and CrVI), arsenic (As),
      and diisocyanates, a possible association with COPD
    explanation: The scoping review identifies several environmental substances, including
      chemicals associated with occupational exposure, that have a strong or possible
      association with chronic obstructive pulmonary disease.
  exposure_term:
    preferred_term: Occupational dust exposure
    term:
      id: ECTO:7000001
      label: exposure to dust
treatments:
- name: Smoking Cessation
  description: Stopping smoking to slow disease progression and improve outcomes.
  evidence:
  - reference: PMID:25496790
    supports: SUPPORT
    snippet: Stopping smoking reduces the risk of developing COPD and is an essential
      treatment for this inflammatory disease. Smoking cessation decreases the prevalence
      of respiratory symptoms, number of hospitalizations, and decline in FEV1, as
      well as exacerbation frequency and overall mortality.
    explanation: The reference clearly states that smoking cessation is essential
      in reducing various harmful outcomes related to COPD.
  - reference: PMID:19811377
    supports: SUPPORT
    snippet: Smoking cessation and lung volume reduction surgery would both qualify
      as disease-modifying interventions.
    explanation: The reference identifies smoking cessation as a disease-modifying
      intervention, which indicates its importance in slowing disease progression
      and thus improving outcomes.
  - reference: PMID:11935838
    supports: SUPPORT
    snippet: The most important intervention is smoking cessation.
    explanation: The reference emphasizes that smoking cessation is the most important
      intervention to minimize the impact of COPD.
  - reference: PMID:27576232
    supports: SUPPORT
    snippet: Smoking cessation is the only intervention shown to slow disease progression.
    explanation: The reference clearly supports the claim that smoking cessation can
      slow disease progression and improve outcomes for COPD patients.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Bronchodilators
  description: Medications that relax muscles of the airways to improve airflow (e.g.,
    beta-agonists, anticholinergics).
  evidence:
  - reference: PMID:29794201
    supports: SUPPORT
    snippet: Bronchodilator therapy can often decrease symptoms of air-flow obstruction
      by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and
      improving quality of life.
    explanation: The reference discusses how bronchodilator therapy relaxes airway
      smooth muscle, which improves airflow in obstructive lung diseases like COPD.
  - reference: PMID:27576232
    supports: SUPPORT
    snippet: Long-acting beta2-agonists and long-acting muscarinic antagonists are
      first-line treatments for patients with persistently symptomatic COPD with an
      FEV1 of 80% or less of predicted.
    explanation: This reference identifies bronchodilators, specifically long-acting
      beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving
      airflow.
  - reference: PMID:28757318
    supports: SUPPORT
    snippet: Combination long-acting inhaled bronchodilators are central to the management
      of patients with moderate to very severe chronic obstructive pulmonary disease.
    explanation: This reference confirms that bronchodilators, such as long-acting
      beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD
      symptoms by improving pulmonary function.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Inhaled Corticosteroids
  description: Reduce airway inflammation and frequency of exacerbations.
  evidence:
  - reference: PMID:20102305
    supports: PARTIAL
    snippet: Short-term treatment with ICS improves lung function and quality of life;
      in addition, several studies with longer follow-up have shown less decline over
      time in quality of life, and fewer exacerbations. By contrast, long-term studies
      have been unable to show substantial improvement in the decline of lung function
      in COPD.
    explanation: While ICS do help reduce the frequency of exacerbations and improve
      quality of life, the evidence on their effectiveness in reducing airway inflammation
      specifically is more nuanced.
  - reference: PMID:37348121
    supports: PARTIAL
    snippet: Current pharmacologic strategies, including first- and second-line therapies
      such as long-acting Œ≤2-agonists, long-acting muscarinic antagonists, inhaled
      corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief
      to patients with COPD
    explanation: ICS are included in the treatment strategies, and while they help
      mitigate exacerbations, the snippet suggests that not all patients experience
      reduced airway inflammation.
  - reference: PMID:29938633
    supports: SUPPORT
    snippet: The major alteration has been in the section concerning treatment with
      inhalation medication - now aiming at an easy stepwise up-titration of long-acting
      medicine as well as a guide of how to down-titrate inhaled corticosteroids.
    explanation: The guideline update underscores the role of ICS in managing stable
      COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.
  - reference: PMID:30846476
    supports: SUPPORT
    snippet: Recent large randomised controlled trials have provided important new
      information concerning the therapeutic effects of ICSs and long-acting bronchodilators
      on exacerbations.
    explanation: The new evidence indicates that ICS are effective in reducing exacerbations,
      supporting their role in treatment.
  treatment_term:
    preferred_term: respiratory tract agent therapy
    term:
      id: MAXO:0000312
      label: respiratory tract agent therapy
- name: Phosphodiesterase-4 Inhibitors
  description: Reduce inflammation and relax airways.
  evidence:
  - reference: PMID:15699784
    supports: SUPPORT
    snippet: Some of the selective PDE4 inhibitors have demonstrated in vitro and
      in vivo anti-inflammatory activity on cells commonly linked to airway inflammation
      in COPD, such as neutrophils.
    explanation: The reference indicates that selective phosphodiesterase 4 inhibitors
      show anti-inflammatory activity, supporting the statement about reducing inflammation.
  - reference: PMID:20649375
    supports: SUPPORT
    snippet: Roflumilast targets inflammatory processes in COPD, with beneficial effects
      on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary
      malfunction and oxidative stress.
    explanation: Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus
      supporting the statement.
  - reference: PMID:34731461
    supports: SUPPORT
    snippet: The orally administered PDE4 inhibitor roflumilast reduces exacerbation
      rates in the subgroup of chronic obstructive pulmonary disease patients with
      a history of exacerbations and the presence of chronic bronchitis, but can cause
      PDE4 related adverse effects due to systemic exposure.
    explanation: This reference confirms the anti-inflammatory effect of PDE4 inhibitors
      which aligns with the statement.
  - reference: PMID:32361678
    supports: SUPPORT
    snippet: Protein kinases have been implicated in mediating inflammatory signals
      and airway remodeling associated with reduced lung function in chronic pulmonary
      disease.
    explanation: This reference supports the role of PDE inhibitors, specifically
      kinase inhibitors, in reducing inflammation in COPD.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Oxygen Therapy
  description: Long-term oxygen use for patients with severe chronic hypoxemia.
  evidence:
  - reference: PMID:24461631
    supports: SUPPORT
    snippet: This therapeutic intervention has been shown to increase survival in
      patients with chronic obstructive pulmonary disease (COPD) and respiratory failure.
    explanation: The literature supports that long-term oxygen therapy (LTOT) is used
      to treat patients with COPD who have severe chronic hypoxemia.
  - reference: PMID:37353334
    supports: SUPPORT
    snippet: Long-term oxygen therapy (LTOT) is a mainstay treatment for patients
      with severe resting hypoxemia secondary to chronic respiratory conditions including
      COPD.
    explanation: This reference specifically mentions LTOT as a primary treatment
      for patients with severe chronic hypoxemia due to COPD.
  - reference: PMID:19462352
    supports: SUPPORT
    snippet: Only smoking cessation and long term oxygen therapy (LTOT) improve survival
      in COPD.
    explanation: This study confirms that LTOT is a treatment that improves survival
      in patients with severe COPD and chronic hypoxemia.
  treatment_term:
    preferred_term: artificial respiration
    term:
      id: MAXO:0000503
      label: artificial respiration
- name: Pulmonary Rehabilitation
  description: Exercise training, education, and support to improve quality of life
    and physical conditioning.
  evidence:
  - reference: PMID:29526182
    supports: SUPPORT
    snippet: PR is an effective and cost-effective therapeutic intervention that improves
      physical performance ability, shortness of breath, and the quality of life in
      patients with COPD.
    explanation: The reference indicates that pulmonary rehabilitation (PR) improves
      physical performance, shortness of breath, and quality of life in COPD patients,
      aligning with the statement&#39;s description of treatments including exercise training,
      education, and support.
  - reference: PMID:34338012
    supports: SUPPORT
    snippet: Exercise improves the physiological and psychological condition of people
      with chronic obstructive pulmonary disease and should be encouraged, with referral
      to a pulmonary rehabilitation service if available.
    explanation: This reference supports the statement&#39;s claim by emphasizing the
      importance of exercise and recommending pulmonary rehabilitation to improve
      the quality of life and physical conditioning in COPD patients.
  - reference: PMID:34955635
    supports: SUPPORT
    snippet: The combination of drug therapy with non-drug therapy such as pulmonary
      rehabilitation training has demonstrated a great potential in reducing the occurrence
      of complications and delaying the progression of COPD.
    explanation: This reference supports the statement by highlighting the benefits
      of pulmonary rehabilitation training, specifically its potential to improve
      quality of life and physical conditioning in COPD patients.
  - reference: PMID:24874124
    supports: SUPPORT
    snippet: Pulmonary rehabilitation targets the systemic manifestations of COPD,
      the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid
      treatment.
    explanation: This reference supports the statement by indicating that pulmonary
      rehabilitation addresses systemic issues in COPD and implies improvement in
      quality of life and physical conditioning.
  - reference: PMID:24507849
    supports: SUPPORT
    snippet: The main objective of pulmonary rehabilitation is to restore muscle function
      and exercise tolerance, reverse other nonrespiratory consequences of the disease,
      and help patients to self-manage chronic obstructive pulmonary disease and its
      exacerbations and symptoms.
    explanation: This reference supports the statement by detailing the benefits of
      pulmonary rehabilitation, including exercise training, education, and support,
      to improve quality of life and physical conditioning.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Lung Volume Reduction Surgery
  description: Surgical removal of damaged lung tissue for severe emphysema.
  evidence:
  - reference: PMID:22189668
    supports: SUPPORT
    snippet: Surgical approaches include lung transplantation and lung volume reduction
      and the latter has been shown to improve exercise tolerance, quality of life,
      and survival in highly selected patients with advanced emphysema.
    explanation: The literature supports the use of lung volume reduction surgery
      as a treatment for severe emphysema in chronic obstructive pulmonary disease
      (COPD) patients.
  - reference: PMID:33926668
    supports: SUPPORT
    snippet: As symptoms and lung function decline, treatment modalities, such as
      lung volume reduction surgery, have been used in individuals with chronic obstructive
      pulmonary disease and upper lobe predominant emphysema.
    explanation: The literature indicates that lung volume reduction surgery is a
      treatment used for severe emphysema, a condition associated with COPD.
  - reference: PMID:31145187
    supports: SUPPORT
    snippet: &#39;Mortality benefits to therapy have been demonstrated in only 2 therapeutic
      interventions to date: long-term use of daily supplemental oxygen and surgical
      lung volume reduction (LVRS) for upper-lobe-predominant disease in patients
      with a low baseline exercise capacity.&#39;
    explanation: The statement is supported as the literature suggests that lung volume
      reduction surgery is an established treatment for upper-lobe-predominant, severe
      emphysema in COPD patients.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Lung Transplantation
  description: Considered in end-stage COPD with severe impairment.
  evidence:
  - reference: PMID:17240617
    supports: SUPPORT
    snippet: Lung transplantation is a surgical option for patients who fail optimization
      of medical treatment for the severe symptoms that result from COPD.
    explanation: This reference states that lung transplantation is a considered treatment
      option for patients with severe symptoms resulting from COPD.
  - reference: PMID:31375190
    supports: SUPPORT
    snippet: End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative
      principles can guide decision making and symptom management in these disease
      states.
    explanation: The reference focuses on end-stage COPD and mentions lung transplantation
      as a consideration in managing the conditions of patients.
  - reference: PMID:36050206
    supports: SUPPORT
    snippet: The International Thoracic Organ Transplant Registry...focus on lung
      transplant recipients with chronic obstructive pulmonary disease.
    explanation: This source concentrates on lung transplantation for patients with
      COPD, in line with the statement&#39;s context of it being a treatment for end-stage
      COPD.
  - reference: PMID:23248802
    supports: SUPPORT
    snippet: Chronic obstructive pulmonary disease...treated by lung transplantation.
    explanation: This abstract explicitly mentions the use of lung transplantation
      for individuals with very severe COPD.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Mucolytic Therapy
  description: N-acetylcysteine and other mucolytics reduce mucus viscosity and may
    improve mucociliary clearance.
  notes: Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression
    and mucus rheology.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Macrolide Antibiotics
  description: Long-term macrolide therapy reduces exacerbation frequency but raises
    antimicrobial resistance concerns.
  notes: Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial
    effects.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Biologic Therapies
  description: Precision biologics targeting Type 2 inflammation in eosinophilic COPD
    subsets.
  notes: Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33
    and anti-TSLP under investigation.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
review_notes: COPD is characterized by progressive airflow obstruction that is not
  fully reversible. Key respiratory symptoms include dyspnea, chronic cough, sputum
  production, and wheezing. As the disease progresses, patients may develop signs
  of lung hyperinflation (barrel chest) and are at risk for respiratory failure. Systemic
  effects like fatigue and weight loss are also common, particularly in advanced disease.
disease_term:
  preferred_term: chronic obstructive pulmonary disease
  term:
    id: MONDO:0005002
    label: chronic obstructive pulmonary disease
classifications:
  harrisons_chapter:
    - classification_value: respiratory system disorder
    - classification_value: obstructive lung disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Chronic_Obstructive_Pulmonary_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>